Journal of Headache and Pain

Papers
(The median citation count of Journal of Headache and Pain is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study509
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition245
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II114
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine89
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis87
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study79
Differences in gray matter volume in episodic migraine patients with and without prior diagnosis or clinical care: a cross-sectional study71
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States67
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries63
Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan61
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials60
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation59
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency58
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache56
Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke51
Characteristics of N400 component elicited in patients who have migraine with aura51
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks50
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study49
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia47
Age- and frequency-dependent changes in dynamic contrast perception in visual snow syndrome47
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine43
Debate: Are cluster headache and migraine distinct headache disorders?42
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China42
Measuring interictal burden among people affected by migraine: a descriptive survey study40
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine40
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients39
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine39
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey39
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury35
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial34
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States33
A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN33
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI33
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study33
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results33
Attenuated alpha oscillation and hyperresponsiveness reveals impaired perceptual learning in migraineurs32
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension31
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study31
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study29
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany29
Correction to: Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic revi29
Inflammatory complications of CGRP monoclonal antibodies: a case series28
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting28
Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials28
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model27
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phas27
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study27
Altered effective connectivity in migraine patients during emotional stimuli: a multi-frequency magnetoencephalography study27
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain27
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism26
Osmophobia in primary headache patients: associated symptoms and response to preventive treatments26
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-ana26
Development and validation of a novel model for characterizing migraine outcomes within real-world data26
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients26
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients25
Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank25
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report25
Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials25
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study25
Tracking the evolution of non-headache symptoms through the migraine attack25
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study25
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies25
Correction: Burden of tension-type headache in the Middle East and North Africa region, 1990-201924
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study24
Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study23
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience23
Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review22
Genome-wide analysis identified novel susceptible genes of restless legs syndrome in migraineurs22
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)22
Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology22
Gradually shifting clinical phenomics in migraine spectrum: a cross-sectional, multicenter study of 5438 patients22
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study22
Contribution of tetrodotoxin-resistant persistent Na+ currents to the excitability of C-type dural afferent neurons in rats22
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients22
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis22
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental ch22
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure21
Prenatal oestrogen-testosterone balance as a risk factor of migraine in adults21
Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 rece21
Effects of a history of headache and migraine treatment on baseline neurocognitive function in young athletes21
Insulin sensitizes neural and vascular TRPV1 receptors in the trigeminovascular system21
Correction: Applying a biopsychosocial model to migraine: rationale and clinical implications21
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients21
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study21
Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine21
Cardiac cephalalgia: a narrative review and ICHD-3 criteria evaluation21
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab21
Long COVID headache20
Enhanced functional connectivity between habenula and salience network in medication-overuse headache complicating chronic migraine positions it within the addiction disorders: an ICA-based resting-st20
Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists20
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts20
CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury20
Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey20
Long term evaluation of a multidisciplinary trigeminal neuralgia service19
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database19
Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis19
The economic and personal burden of cluster headache: a controlled cross-sectional study19
Functional correlation of ATP1A2 mutations with phenotypic spectrum: from pure hemiplegic migraine to its variant forms18
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension18
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update18
Is there a causal relationship between stress and migraine? Current evidence and implications for management18
Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results18
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience18
Interictal osmophobia is associated with longer migraine disease duration18
The prevalence of primary headache disorders in children and adolescents in Zambia: a schools-based study18
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study17
CGRP outflow into jugular blood and cerebrospinal fluid and permeance for CGRP of rat dura mater17
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study17
Regional cerebral blood flow as predictor of response to occipital nerve block in cluster headache17
Correction: A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan17
Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup17
Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms16
Correction to: Hyperbaric oxygen attenuates neuropathic pain and reverses inflammatory signaling likely via the Kindlin-1/Wnt-10a signaling pathway in the chronic pain injury model in rats16
A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine16
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study16
TIME, to move forward? comment on “a universal outcome measure for headache treatments, care-delivery systems and economic analysis”16
The Global Campaign turns 18: a brief review of its activities and achievements16
The International Headache Congress – IHS and EHF joint congress 202116
Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine16
0.048304080963135